Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1 –3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial

CARTITUDE-4 (NCT04181827) is a phase 3 trial comparing ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen chimeric antigen receptor-T cell (CAR-T) therapy, with standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in patients (pts) with lenalidomide (len)-refractory multiple myeloma (MM). Pts in the cilta-cel arm had significantly improved progression-free survival (PFS), higher rates of ≥complete response (CR), and higher overall response rate (ORR) versus SOC in the intent-to-treat (ITT) set.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: M Hasib Sidiqi, Paolo Corradini, Duncan Purtill, Hermann Einsele, Binod Dhakal, Lionel Karlin, Salomon Manier, Shinsuke Iida, Sebastian Giebel, Simon J Harrison, Brea Lipe, Dr. Abdullah Mohammad Khan, Jordan M Schecter, Carolyn C Jackson, Tzu-min Yeh, Arn Tags: 514 Source Type: research